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Abstract 
Adenosine 5'-diphosphate (ADP) caused rapid and significant reductions in the rates of [3H]serotonin uptake observed for human 
platelets, human platelet vesicles, and rat brain synaptic vesicles. Estimated Vma ~ values in platelets (N = 15), platelet vesicles (N = 3), 
and synaptic vesicles (N= 3) exposed to 100 IxM ADP were 42.3_ 11.4%, 78.8+ 1.4%, and 56.8+9.9% of control values, 
respectively. The ECso values observed for ADP in platelets and platelet vesicles were 10-24 I~M. Exposure to 100 IxM ADP had small, 
inconsistent effects on K M values observed for the platelet transporter. ADP (100 I~M) caused only a slight competitive inhibition of the 
platelet membrane binding of [3H]citalopram, a ligand for the 5HT uptake site of the transporter (5.0% displacement of 1.0 nM 
[3H]citalopram, 13% increase in apparent KD). 
The ADP analogue 2-methylthioADP caused similar decreases in the rates of platelet [3H]serotonin uptake, while a number of other 
related compounds had little or no effect on rates of platelet uptake. The ADP-effect on uptake was rapid, occurring in less than 2.5 s, and 
was additive with reductions produced by protein kinase C (PKC) activation. The ADP-induced decreases in uptake did not appear to 
occur through the ADP receptor or known platelet second messenger systems. The exact mechanism of the ADP-effect and its functional 
significance remain to be determined. 
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1. Introduction 
The widespread use of pharmacological gents which 
block monoamine neurotransmitter uptake is a testament to 
their potent behavioral effects and a reflection of the 
critical role of the uptake process in central neurotransmis- 
sion. Recent research has elucidated primary and sec- 
ondary structures of the plasma membrane serotonin (5HT), 
dopamine, and norepinephrine transporters, and has in- 
creased our understanding of their function [1-5]. 
It is of considerable interest to determine whether 
monoamine uptake is physiologically regulated, and to 
ascertain the mechanism and extent of the possible regula- 
tion. It is clear that most transport systems [6], including 
those for sugars [7,8], various anions and cations [9,10], 
and amino acids [11], are highly regulated. Regulation of 
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these systems is often receptor-mediated and can occur 
both through rapid conformational/chemical modifications 
and longer-term changes in levels of transporter expres- 
sion. 
There has been a continuing interest in the regulation of 
monoamine uptake [12-20]. Research in this area has 
increased recently with reports of short-term regulation of 
5HT uptake after protein kinase C activation [21,22], 
calmodulin inhibition [23], ethanol treatment [24], and 
adenosine receptor stimulation [25]. Long-term regulation 
through altered levels of transporter expression has been 
reported after protein kinase A activation [26-28] and 
following the chronic administration of antidepressants 
[29-32] and estradiol [16]. In preliminary studies we have 
reported on a rapid, marked, decrease in platelet 5HT 
uptake after exposure to adenosine 5'-diphosphate (ADP) 
[33,34]. Reported here are studies characterizing the ADP- 
effect on 5HT uptake in human platelets, platelet vesicles, 
and rat brain synaptic vesicles, and examining the mecha- 
nism of the effect in platelets. 
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2. Experimental procedures 
2.1. Materials 
Sodium nitroprusside, epinephrine, serotonin, desim- 
pramine, staurosporine, mezerein, and adenosine diphos- 
phate (ADP) and related compounds were purchased from 
Sigma (St. Louis, MO). The compounds 2-methylthio- 
adenosine diphosphate (2MeSADP), 2-methylthioadeno- 
sine triphosphate (2MeSATP), and 8-bromo-cyclic guano- 
sine monophosphate (8-BrcGMP) were obtained from RBI 
(Natick, MA). [3H]Serotonin ([3H]5HT) creatinine sulfate 
was purchased from Amersham (Arlington Heights, IL), 
[3H]citalopram was purchased from New England Nuclear 
(Boston, MA). Fluoxetine was a gift of the Eli Lilly Co. 
2.2. Platelet [3H]5HT uptake 
Blood from normal, healthy, unmedicated, adult volun- 
teers was drawn into syringes containing (9:1, v/v) acid 
citrate-dextrose (ACD, NIHA). After centrifugation for 10 
min at 190 ×g using a swinging-bucket rotor, the 
platelet-rich plasma (PRP) was drawn off and the erythro- 
cyte layer centrifuged for 10 min at 1200 X g to prepare 
platelet-poor-plasma (PPP). The platelet concentration of
the PRP was adjusted to 2.13 • 108/ml with the autologous 
PPP and further diluted with 9 vols. of platelet uptake 
buffer (calcium-free pH 7.4 Krebs-Henseleit phosphate 
buffer; 6.92 g NaC1, 0.35 g KC1, 0.29 g MgSO4.7H20, 
0.16 g KH2PO4, 2.1 g NaHCO3, 2.1 g glucose per liter). 
The diluted platelets were maintained at 37°C prior to use 
in the 5HT uptake assay. Platelet [3H]5HT uptake assays 
were performed in siliconized 12 X 75-mm glass tubes in a 
final volume of 0.5 ml containing 107 platelets. Platelets 
were preincubated at 37°C with the various agents for 
specified times prior to the addition of [3H]5HT. The 
incubation was continued 1 min after the addition of 
[3H]5HT, at which time uptake was terminated by diluting 
the sample with 4 ml of ice-cold platelet uptake buffer and 
rapid filtration through GF/C glass-fiber filters (What- 
man). The tubes and filters were washed twice with 4-ml 
vols. of cold buffer, and the collected [3H]5HT determined 
by liquid scintillation counting. Each point was determined 
in triplicate. Non-specific incorporation was determined by 
including the 5HT uptake inhibitor fluoxetine (10 IxM). 
Values for Vma x and K M were calculated by the method of 
Eadie and Hofstee [35]. In most experiments, the Vma x was 
assumed to be equal to the uptake observed at 1 IxM 5HT. 
2.3. Platelet vesicle [3H]5HT uptake 
diluting the thawed vesicle suspension 10-fold with pH 
6.7, 10 mM K3PO 4 buffer containing 133 mM KeSO 4 and 
1 mM MgSO 4 (final protein concn. 2.6 mg/ml). After a 
30 min incubation at 37°C, 15 or 20 ~1 of the diluted 
K+-loaded vesicle suspension was added to platelet vesicle 
uptake buffer (pH 6.7, 10 mM Li3PO 4 containing 200 mM 
NaC1 and 1 mM MgSO 4) and uptake initiated by adding 
appropriate amounts of [3H]5HT (final total volume 1.0 
ml). Uptake was allowed to proceed for 2 min (37°C) and 
was terminated by diluting with ice-cold 212 mM NaC1, 
the vesicles were then collected by rapid filtration on 
nitrocellulose filters (0.5 ~m pore size, Whatman) [36]. 
2.4. Rat brain synaptic vesicle [3H]5HT uptake 
Synaptic vesicles were prepared by manually homoge- 
nizing whole rat brain (less cerebellum) in 15 volumes 
(v/w) of ice-cold 0.32 M sucrose using a Kontes-Duall 
tissue grinder (PTFE-glass, 0.10-0.015 clearance). The 
homogenate was centrifuged 10 min at 1000 × g (0-4°C), 
the supernate then centrifuged at 20 000 × g to obtain a 
'P2' pellet. The pellet was resuspended in 20 volumes 
(vols./original wet weight) of 0.32 M sucrose and kept on 
ice; vesicles were not assayed for uptake until at least 20 
min following resuspension. Vesicle uptake was assayed as 
for platelet uptake xcept hat 100 OA of vesicle suspension 
was added to the platelet uptake buffer (final total volume 
1.0 ml) at least 5 min before initiating uptake by the 
addition of [3H]5HT; an uptake period of 2 min was used. 
2.5. Platelet membrane [3H]citalopram binding 
Platelet membranes were prepared from outdated platelet 
concentrate (American Red Cross) as previously described 
[37]. [3H]Citalopram (81 IxCi/mmol) binding was assayed 
in a manner similar to that previously used to determine 
platelet [3H]imipramine binding [37]. Studies were per- 
formed in a total volume of 300 Ixl, saturation studies used 
concentrations of [3H]citalopram of from 0.25 to 4.0 nM 
with 10 txM fluoxetine added to define non-specific bind- 
ing. Displacement experiments were performed using 1.0 
or 1.5 nM [3H]citalopram. 
All data are expressed as mean ___ standard eviation 
(S.D.). 
3. Results 
3.1. Effect of ADP and 2MeSADP on platelet [3H]5HT 
uptake 
Platelet membrane vesicles, prepared by hypotonic lysis 
of outdated human platelet concentrates a previously de- 
scribed [35], were kindly supplied by Dr. Gary Rudnick. 
The platelet vesicles (26 mg/ml) were stored at -70°C 
until assayed for uptake. Uptake was determined after 
As seen in Fig. 1, exposure of platelets to 20 or 100 
IxM ADP during the 1 min uptake period caused marked 
decreases in the rate (Vma x) of platelet [3H]5HT transport, 
with no consistent effect on K M. The effect was near 
maximal at 100 IxM ADP (see Fig. 2a), with an average 
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Fig. 1. Effect of ADP on platelet [3H]5HT uptake. Platelets were exposed 
to 0, 20, or 100 IxM ADP during a 1 min uptake period, using 5HT 
concentrations ranging from 0.05 to 1.0 ixM. Experiments were per- 
formed with a 1 min uptake period, at 37°C. Uptake is expressed as 
specific incorporation per 109 platelets (mean + S.D. of triplicate sam- 
ples). Similar results were obtained in a second saturation experiment. 
(+S.D.)  decrease in Vma x tO 42.3 ___ 11.4% (N= 15) of 
control values (Vma x estimated from uptake at 1.0 ixM). An 
ECs0 of 24__+ 15 IxM ADP was observed (N= 5). As 
shown in Fig. 2b, similar decreases in the estimated Vma x 
(determined from the uptake rate observed at 1 IxM 5HT) 
were seen when platelets were exposed to the hydrolysis- 
resistant ADP analogue 2MeSADP during the uptake pe- 
riod. On average, the estimated Vma x decreased to 55.9 + 
2.1% (N=3)  of control in the presence of 10 txM 
2MeSADP. The effect was maximal at 10 IxM 2MeSADP, 
ECs0 values for 2MeSADP ranged from 0.4 to 4.0 txM 
(mean 1.7 IxM). 
3.2. Temporal aspects of the ADP-induced decrease in 
platelet [ 3 H]5HT uptake 
Initial experiments revealed that no preincubation pe- 
riod was necessary for maximal inhibition of [3H]5HT 
uptake by ADP. However, because platelets were exposed 
to ADP throughout the 1 min uptake period it was unclear 
just how rapidly the ADP effects were manifest. When 
uptake was measured in uptake periods ranging from 2.5 to 
60 s, a significant (P  < 0.05) decrease was seen even for 
the briefest exposure/uptake time of 2.5 s (see Fig. 3). 
3.3. Effect of platelet actiuators on platelet [3H]5HT up- 
take 
Because ADP is known to cause an inhibition of platelet 
adenylate cyclase and an increase in platelet Ca 2 ÷ concen- 
tration [38], we examined the effects of epinephrine (EPI, 
an inhibitor of platelet adenylate cyclase), of the calcium 
ionophore A23187, and of the two agents in combination. 
Five min preincubation with either 10 IxM EPI, 100 lxM 
EPI, 1 IxM A23187, 10 IxM A23187, or a combination of 
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Fig. 2. Concentration dependence of ADP and 2MeSADP effects on 
platelet [3H]5HT uptake. (a) Platelet 5HT uptake observed in five differ- 
ent subjects. Uptake was carried out in the presence of 0, 1, 5, 20, 50 or 
100 p,M ADP. (b) Platelet 5HT uptake observed in two different subjects. 
Platelets were exposed to 0, 0.05, 0.1,0.5, 2.0, 5.0 and 10 la, M 2MeSADP. 
Experiments were performed with 1 IzM 5HT, I min uptake period, at 
37°C. 
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Fig. 3. Time dependence of the ADP effect on platelet [3H]5HT uptake. 
Platelet [3H]5HT uptake was measured for a range of uptake periods 
ranging from 2.5 to 60 s. Uptake was determined using 1 I~M 5HT in the 
presence and absence of 100 IxM ADP. Significant reductions were seen 
for all uptake periods examined (P = 0.001 for 5-60 s uptake periods, 
P = 0.05 for 2.5 s, according to Students' t-test. 
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inhibition. Similar additive effects were seen when dose- 
response curves for mezerein with or without ADP (100 
IxM) were obtained (Fig. 4b). The PKC inhibitor stau- 
rosporine, shown previously to block the inhibitory effects 
of PKC activation on [3H]5HT uptake [22], at concentra- 
tions of 0.1-10 IxM had no apparent effect on the down- 
regulation produced by 100 txM ADP. The possible in- 
volvement of cyclic guanosine monophosphate (cGMP)- 
dependent protein kinase (PKG) in the regulation of platelet 
5HT uptake was examined by pretreatment with the cell- 
permeant cGMP analogue 8-bromo-cGMP. No effect on 
uptake was seen over a concentration range of 1 p,M to 2 
mM, with pretreatment times of up to 20 min (data not 
shown). 
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Fig. 4. Effect of the combination f a PKC activator and ADP on platelet 
[3H]5HT uptake. (a) Platelets were preincubated (20 min) with the 
indicated concentrations of mezerein, uptake (1.0 ixM 5HT, 1 min) was 
then carried out in the presence of 5-100 ~M ADP. (b) Platelets were 
preincubated (20 min) with a range of mezerein concentrations (1 nM-1 
IxM), uptake (1.0 IxM 5HT, 1 min) was then measured in the presence 
(100 IxM) or absence ofADP. Values are means (+ S.D.). 
3.5. Effects of ADP-related compounds on platelet 
[ 3H]5HT uptake 
A range of purine derivatives and other ADP-related 
compounds, including adenine, adenosine, 2-chloroadeno- 
sine, adenosine monophosphate (AMP), cyclic AMP, 
adenosine triphosphate (ATP), 2MeSATP, guanosine 
monophosphate, guanosine diphosphate, guanosine 
triphosphate, theophylline, theobromine, and caffeine, were 
tested for their possible effect on platelet [3H]5HT uptake 
(concn. of agents 0.1 or 1 mM, 0.15 txM 5HT, 1 min 
uptake period). Uptake rates observed in the presence of 
all but one of the compounds tested ranged from 92.3 to 
108% of control, and were not significantly different from 
control. However, 2MeSATP did significantly reduce up- 
take to 76.8-82.2% of the control value (P  values 0.0001 
and 0.03). In the same series of experiments 100 ixM ADP 
reduced uptake to 56.3 + 6.8% (N = 3) of control. 
3.6. Effect of ADP on platelet uesicle [3H]5HT uptake 
10 IxM EPI and 10 p,M A23187 had little or no (< 5% 
reduction) effect on the rate of platelet [3H]5HT uptake. 
Preexposure to the nitric oxide source sodium nitroprus- 
side (2-50 txM) had no effect on basal platelet [3H]5HT 
uptake, and was without effect on the reduction in uptake 
rate caused by 100 p,M ADP (data not shown). 
3.4. Effects of protein kinase modulation on platelet 
[3H]5HT uptake 
In order to study the relationship of the ADP-mediated 
effect to the previously described down-regulation of 
platelet uptake caused by protein kinase C (PKC) activa- 
tors [21,22], we examined the effects of the PKC activator 
mezerein in combination with either ADP or 2MeSADP. 
As shown in Fig. 4a the effects of mezerein and ADP were 
additive, with a range of mezerein concentrations causing 
relatively constant additional percentage declines in 
[3H]5HT uptake regardless of the extent of ADP-induced 
As seen in Fig. 5a, exposure of platelet vesicles to ADP 
during the 2 min uptake period significantly decreased the 
rate of [3H]5HT uptake. Uptake at 1.0 p,M 5HT averaged 
78.8 + 1.4% (N = 3) of control in platelets exposed to 100 
txM ADP. There was little effect of ADP on the affinity 
(K M) of the transporter for 5HT. An apparent ECs0 of 10 
IxM was observed for the ADP-induced reduction in the 
rate of platelet vesicle 5HT uptake. 
3. 7. Effect of ADP on rat brain synaptic vesicle [~H]5HT 
uptake 
Synaptic vesicles exposed to ADP during the 2 min 
uptake period showed significantly lower rates of [3H]5HT 
uptake compared to controls (see Fig. 5b). Synaptosomal 
uptake observed at 1.0 IxM 5HT was 56.8 + 9.9% (N = 3) 
of controls in the presence of 100 txM ADP. Similar 
reductions were seen in the Vma x values calculated from 
Eadie-Hofstee analysis; with only small increases in cal- 
culated K M values. An apparent ECs0 of 15 p.M was 
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Fig. 5. Effect of ADP on platelet and synaptic vesicle [3H]5HT uptake. 
(a) Platelet vesicles were exposed to 0 or 100 txM ADP during a 2 min 
uptake period, 5HT concentrations ranged from 0.05 to 1.0 I~M. Uptake 
is expressed as specific (not fluoxetine blocked) incorporation per 2 min 
per tube (50 ~g vesicle protein per tube). Graph is representative of two 
saturation experiments carried out with platelet vesicles. (b) Synaptic 
vesicles were exposed to 0 or 100 txM ADP during a 2 min uptake 
period. Specific uptake was expressed as incorporation per 2 min per tube 
(P2 fraction equivalent to 5 mg original wet weight brain per tube). Graph 
is representative of two saturation experiments carried out with synaptic 
vesicles. 
observed for ADP. Similar effects of ADP on the rate of 
5HT uptake were observed when 2 mM Ca z+ was added 
to the uptake buffer (data not shown). 
3.8. Effect of ADP on platelet membrane [3H]citalopram 
binding 
Exposure of platelet membranes to 100 ixM ADP dur- 
ing the 60 min (22°C) incubation period caused a slight 
increase (+ 13%) in the apparent K D for [3H]citalopram 
and was without effect on the observed Bma x. In displace- 
ment experiments, 100 I~M ADP caused only a 5.0% 
inhibition of 1.0 nM [3H]citalopram binding. In contrast, 
nearly complete displacement of [3H]citalopram was seen 
with fluoxetine (IC50 = 4.0 nM) and desipramine (IC50 = 
71 nM). 
Due to the potential for metabolism of ADP over the 60 
min incubation period, binding experiments were also 
carded out using the hydrolysis-resistant 2MeSADP and 
with shorter incubation times. The addition of ADP (10 
and 100 txM) during shorter term incubations (non-equi- 
librium conditions: 5 and 10 min, 22°C) of platelet mem- 
branes with [3H]citalopram had little or no effect on 
binding (< 5% displacement). Similarly, the presence of 
2MeSADP (1.0 and 10 p~M) failed to appreciably affect 
the binding of [3H]citalopram seen after a 60 min incuba- 
tion (data not shown). In studies on the effect of increasing 
serotonin concentrations (0.05 to 2.5 ~zM) on 
[3H]citalopram binding to platelet membranes, ADP (100 
IxM) and 2MeSADP (10 ixM) did not influence the dis- 
placement of [ 3 H]citalopram by serotonin (data not shown). 
4. Discussion 
ADP is a well-studied platelet activator, causing shape 
change, aggregation, calcium influx and inhibition of 
adenylate cyclase [38]. The reduction in platelet 5HT 
uptake does not appear to be due to these secondary effects 
of ADP. Studies were done in non-aggregating, on-releas- 
ing, conditions (diluted PRP, low Ca 2 ÷ ) and several agents 
which cause platelet shape change (including 5HT itself) 
did not cause a reduction in uptake. 
The possible involvement of Ca 2÷, cyclic adenosine 
monophosphate (cAMP), and other second messenger sys- 
tems was studied; Ca 2÷ and cAMP were of particular 
interest given ADP's effects on both these intracellular 
signals. The calcium ionophore A23187 failed to affect 
[3H]5HT uptake at concentrations and pretreatment times 
known to cause substantial increases in intracellular Ca 2+. 
Epinephrine, at concentrations reported to markedly inhibit 
platelet adenylate cyclase activity, also had no effect on 
uptake rates. It should be noted that in previous experi- 
ments we have not observed any change in uptake after 
exposure to dibutyryl cAMP, an activator of protein kinase 
A (unpublished data), and that the reported effects of PKA 
activation on uptake in a placental cell line occurred after 
4-8 h of exposure to PKA activators [26,27]. When EPI 
and A23187 were combined in an attempt to duplicate the 
known second-messenger effects of ADP, there was still 
no effect on platelet [3H]5HT uptake rates. 
Activation of PKC has been reported to decrease the 
rate of 5HT transport in several cell types [21,22,25]. The 
possible mechanisms of this effect have been explored [22] 
and site-directed mutagenesis experiments have begun to 
localize possible sites of PKC regulation [39,40]. We were 
therefore quite interested in studying the relationship of the 
PKC-induced own-regulation to the ADP-mediated effect. 
In studies combining the PKC activator mezerein with 
either ADP or 2MeSADP, the effects appeared to be 
additive. The lack of an effect of the PKC inhibitor 
staurosporine on the ADP-mediated ecrease in uptake 
provides additional evidence supporting the idea that PKC 
activators and ADP are acting to decrease [3H]5HT uptake 
through distinct and independent processes. 
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In experiments examining the effect of the cGMP-de- 
pendent protein kinase (PKG) activator, 8-BrcGMP, over a 
range of concentrations and treatment times, we found 
virtually no change in platelet [3H]5HT uptake. As men- 
tioned, PKA activation also did not alter platelet [3H]5HT 
uptake or influence the ADP effect. The PKG findings 
contrast with the reported increase of approximately 20% 
in [3H]5HT uptake observed for rat basophilic leukemia 
(RBL) cells after a 15 min treatment with 10 txM 8- 
BrcGMP [25]. Although further research is necessary to 
establish the dose-response characteristics of 8-BrcGMP 
in RBL cells, it appears that the regulation of the trans- 
porter in platelets and RBL cells may be dissimilar in this 
respect. 
Recent reports of an effect of nitric oxide on 5HT 
transport in RBL cells [25] and on dopamine transport in 
rat striatal synaptosomes [41] stand in contrast to our 
findings of unchanged platelet [ 3 H]5HT uptake after prein- 
cubation with sodium nitroprusside. The observed lack of 
an effect of sodium nitroprusside on the platelet Vma x and 
on the ADP-induced reduction in Vma x strongly suggests 
that nitric oxide does not regulate or mediate ADP-regu- 
lation of the platelet 5HT transporter. 
The idea that the ADP effect does not proceed through 
the ADP receptor or second messenger systems is strongly 
supported by the results obtained using platelet vesicles 
and rat brain synaptic vesicles. There is a robust ADP 
effect on 5HT uptake in both types of vesicles, despite the 
virtual elimination of intracellular and extracellular Ca 2÷ 
in the vesicle preparations. Other second messenger sys- 
tems would also be expected to be eliminated or severely 
curtailed in the vesicle systems. In addition, there is little 
reason to believe that the ADP receptor and the serotonin 
transporter are colocalized on neurons of the central ner- 
vous system. The demonstration of the ADP effect in 
synaptic vesicles is, therefore, further evidence against he 
effect being mediated through the ADP receptor. 
Although ADP appears to reduce the rate of platelet 
[3H]5HT uptake by acting at the transporter, it produces 
only small decreases in the apparent affinity of [3H]5HT 
for the transporter and it has only a small inhibitory effect 
on [3H]citalopram binding to the transporter. This similar- 
ity with respect o 5HT and citalopram is expected as thay 
are both considered to bind, in a largly overlapping man- 
ner, to the uptake site of the transporter [42]. Further 
evidence that ADP does not act by altering 5HT binding 
comes from the data showing no effect of ADP on the 
displacement of [3H]citalopram by 5HT. Thus, while it 
seems likely that ADP acts directly on the transporter, it
appears to act at a site which is largely distinct from the 
uptake site itself and it does not act through an alteration 
in the initial binding of 5HT. Rather, it may be that ADP 
acts to alter some aspect of the subsequent translocation 
process. 
The data serve to raise several issues for consideration. 
First, one can speculate that in certain circumstances inhi- 
bition of platelet 5HT uptake by ADP may lead to in- 
creased 5HT-mediated platelet activation and recruitment. 
There is also the possibility that, if the plasma membrane 
5HT transporter were to be incorporated into the granule 
membrane in an outward-directed fashion (for instance, 
after granule fusion and recycling) granular ADP would 
serve to inhibit the misplaced (adventitious) transporter. 
This might limit potentially harmful reductions in granular 
5HT and increases in cytosolic 5HT. 
A second issue concems the general area of non-compe- 
titive inhibition of the 5HT transporter. It appears that, if 
ADP does directly interact with the transporter, it does not 
bind to sites which overlap substantially with the 5HT 
uptake site itself. This is in direct contrast o the large 
family of selective and non-selective competitive serotonin 
reuptake inhibitors. Instead, ADP could be considered to 
have the properties of an encoid or regulatory agent. Much 
of the previous speculation along these lines focused on 
the possibility of non-competitive r gulation through the 
'imipramine binding site'. It is now clear that the 
imipramine binding site is the same as, or largely overlap- 
ping with, the 5HT uptake site [43,44]. However the ADP 
data indicate that it may be possible to have an agent that 
interacts with the transporter without substantially overlap- 
ping with the uptake site. 
To summarize our findings regarding the effects of 
ADP on platelet 5HT uptake: The ADP-mediated effect is 
rapid and predominantly noncompetitive, appears not to 
proceed through second messenger systems or the ADP 
receptor, and is additive with the previously established 
PKC effect on uptake. The functional significance and 
precise mechanism of the ADP-effect remain to be deter- 
mined. 
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